ERRATUM

A. Messori · P. Becagli · S. Trippoli · E. Tendi

Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer

In: Eur J Clin Pharmacol (1996) 51: 111–116

In the above article the sensitivity analysis described on page 114 (last paragraph) erroneously stated that the incremental cost-effectiveness ratio was \$ 48 per life year gained.

The correct value was \$ 485.